³»½Ã°æ ¿ªÇà Ãé´ã°ü Á¶¿µ¼ú ½ÃÀå ±Ô¸ð, Á¡À¯À², µ¿Ç⠺м® º¸°í¼­ : Á¦Ç° À¯Çüº°, ½Ã¼ú À¯Çüº°, ÃÖÁ¾ ¿ëµµº°, Áö¿ªº°, ºÎ¹®º° ¿¹Ãø(2025-2030³â)
Endoscopic Retrograde Cholangiopancreatography Market Size, Share & Trends Analysis Report By Product (Endoscopes, Endotherapy Devices), By Procedure Type (Biliary Sphincterotomy), By End-use (Hospitals), By Region, And Segment Forecasts, 2025 - 2030
»óǰÄÚµå : 1631483
¸®¼­Ä¡»ç : Grand View Research, Inc.
¹ßÇàÀÏ : 2024³â 12¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 120 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,950 £Ü 8,194,000
Unprintable PDF & Excel (Single User License) help
º¸°í¼­ PDF ¹× ¿¢¼¿À» 1Àθ¸ »ç¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, Àμâ´Â ºÒ°¡´ÉÇÕ´Ï´Ù.
US $ 6,950 £Ü 9,571,000
Printable PDF & Excel (5-User License) help
º¸°í¼­ PDF ¹× ¿¢¼¿À» µ¿ÀÏ ±â¾÷ ³» µ¿ÀÏ ºÎ¼­¿¡¼­ ÃÖ´ë 5¸í±îÁö »ç¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, Àμâ´Â °¡´ÉÇÕ´Ï´Ù.
US $ 8,950 £Ü 12,325,000
Printable PDF & Excel (Enterprise License) help
º¸°í¼­ ±¸¸Å ±â¾÷ ¹× ±× ÀÚȸ»ç, °ü°è»ç°¡ »ç¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀ̸ç, PDF ¹× ¿¢¼¿ ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, ÀμⰡ °¡´ÉÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

½ÃÀå ±Ô¸ð ¹× µ¿Çâ

Àü ¼¼°è ³»½Ã°æ ¿ªÇà Ãé´ã°ü Á¶¿µ¼ú ½ÃÀå ±Ô¸ð´Â 2024³â 21¾ï 7,000¸¸ ´Þ·¯·Î ÃßÁ¤µÇ¸ç, 2025-2030³â µ¿¾È ¿¬Æò±Õ 8.26%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ·¯ÇÑ ¼ºÀåÀº ´ã¼®, ÃéÀå¿°, ´ã°üÆó»ö°ú °°Àº ÃéÀå ¹× ´ãµµ ÁúȯÀÇ À¯º´·ü Áõ°¡°¡ ERCP ½Ã¼ú¿¡ ´ëÇÑ ¼ö¿ä¸¦ ÃËÁøÇϰí Àֱ⠶§¹®ÀÔ´Ï´Ù. 2024³â 2¿ù¿¡ ¹ßÇ¥µÈ Clinical Gastroenterology and HepatologyÀÇ Á¶»ç¿¡ µû¸£¸é, ´ã¼®ÀÇ À¯º´·üÀº Àü ¼¼°èÀûÀ¸·Î ¾à 6%·Î ÃßÁ¤µÇ¸ç, ¿©¼º°ú ³²¹Ì¿¡¼­ °¡Àå ¸¹ÀÌ ¹ß»ýÇÏ´Â °ÍÀ¸·Î ³ªÅ¸³µ½À´Ï´Ù. ¿¬±¸¿¡ µû¸£¸é ´ã¼® À¯º´·üÀº ¿¹Ãø ±â°£ µ¿¾È ±ÞÁõÇÒ °ÍÀ¸·Î ¿¹»óµÇ¾î ³»½Ã°æ ¿ªÇà Ãé´ã°ü Á¶¿µ¼ú(ERCP) ½Ã¼ú¿¡ ´ëÇÑ ¼ö¿ä¸¦ ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¶ÇÇÑ, ³»½Ã°æ ±â¼úÀÇ ¹ßÀüÀ¸·Î ERCP ½Ã¼úÀÇ ¾ÈÀü¼º°ú À¯È¿¼ºÀÌ Çâ»óµÇ°í ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, Advantech´Â 2023³â 1¿ù ³»½Ã°æ ±â¼ú ºÎ¹®ÀÇ È¹±âÀûÀÎ Çõ½ÅÀ¸·Î MIO-5377R ½Ì±Û º¸µå ÄÄÇ»Å͸¦ Ãâ½ÃÇß½À´Ï´Ù. ÀÌ ÄÄÆÑÆ®ÇÏ°í °­·ÂÇÑ ÀåÄ¡´Â ³»½Ã°æÀÌ Á÷¸éÇÑ ±âÁ¸ ¹®Á¦¸¦ ÇØ°áÇϱâ À§ÇØ ¼³°èµÇ¾î ¼º´É, ½Å·Ú¼º ¹× ±â´É¼ºÀ» Çâ»ó½ÃÄ×½À´Ï´Ù. ¶ÇÇÑ, °íÈ­Áú ¿µ»ó, ³»½Ã°æÀÇ Á¶ÀÛ¼º Çâ»ó, Ä¡·á¿ë ¾×¼¼¼­¸® °³¹ß µîÀÇ ±â¼ú Çõ½ÅÀ¸·Î ERCP´Â ´õ¿í Á¤¹ÐÇϰí È¿°úÀûÀÎ Áø´Ü ¹× Ä¡·á µµ±¸°¡ µÇ¾ú½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¼úÀû Áøº¸·Î ÀÎÇØ ÀÇ·áÁø°ú ȯÀÚ ¸ðµÎ ERCP¸¦ ¼±ÅÃÇÏ°Ô µÇ¾ú½À´Ï´Ù.

ÃÖ¼Òħ½À ¼ö¼úÀÇ Ã¤ÅÃÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ERCP ½Ã¼ú¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖÀ¸¸ç, ÇâÈÄ ¸î ³â µ¿¾È »ê¾÷ ¼ºÀåÀ» ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿¹¸¦ µé¾î, 2024³â 1¿ù¿¡ ¹ßÇ¥µÈ ¹Ì±¹ ¾Ï ÇùȸÀÇ ¿¬·Ê º¸°í¼­¿¡ µû¸£¸é, ¹Ì±¹¿¡¼­´Â ¾à 41,630°ÇÀÇ °£¾ÏÀÌ »õ·Î Áø´ÜµÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¶ÇÇÑ °°Àº ¼Ò½ÄÅë¿¡ µû¸£¸é °£¾ÏÀº ¹Ì±¹¿¡ ºñÇØ µ¿³²¾Æ½Ã¾Æ ¹× »çÇ϶ó »ç¸· À̳² ±¹°¡µé¿¡¼­ ´õ ÈçÇÑ °ÍÀ¸·Î ³ªÅ¸³µ½À´Ï´Ù. ¶ÇÇÑ, °£¾ÏÀº Àü ¼¼°èÀûÀ¸·Î ¾Ï °ü·Ã »ç¸ÁÀÇ ÁÖ¿ä ¿øÀÎÀ¸·Î ¸Å³â 70¸¸ ¸í ÀÌ»óÀÇ ¸ñ¼ûÀ» ¾Ñ¾Æ°¡°í ÀÖ½À´Ï´Ù.

´ã°ü¾Ï°ú °£¼¼Æ÷¾ÏÀÇ ºÎ´ãÀÌ Å« ¸¸Å­, ÀÌ·¯ÇÑ ¾Ç¼º Á¾¾çÀÇ Á¶±â ¹ß°ßÀ» À§ÇÑ ³»½Ã°æ ¿ªÇà Ãé´ã°ü Á¶¿µ¼ú¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¶ÇÇÑ ÃéÀå ¹× ´ãµµ ÁúȯÀÇ Á¶±â Áø´Ü ¹× Ä¡·áÀÇ ÀÌÁ¡¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö¸é¼­ ERCP¿Í °°Àº ÃÖ¼Òħ½ÀÀû ½Ã¼ú¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, 2023³â 10¿ù, ´ãµµÆó¼âÁõ Àνݳ¼±À§¿øÈ¸´Â ÇÏ¿ìÅÞÁÖ °íÇü Àå±â ÀÌ½Ä ºÎ¼­¿Í À§Æ®¿öÅͽ½·£µå´ëÇб³ ¼£·Ô ¸Æ¼¼Å° Çмúº´¿øÀÇ ÈÄ¿øÀ¸·Î ´ãµµÆó¼âÁõ Àνݳ¼± Ä·ÆäÀÎÀ» ½ÃÀÛÇß½À´Ï´Ù. ÀÌ Ä·ÆäÀÎÀº ´ã°üÀÌ ¸·È÷°Å³ª ¼Ò½ÇµÇ¾î ¿µÀ¯¾Æ°¡ °É¸®´Â Èñ±ÍÇÏ°í »ý¸íÀ» À§ÇùÇÏ´Â °£ ÁúȯÀÎ ´ãµµÆó¼âÁõ¿¡ ´ëÇÑ ÀÎ½Ä °³¼±°ú ¾î¸°ÀÌ È¯ÀÚµéÀ» µ½±â À§ÇÑ Ä·ÆäÀÎÀÔ´Ï´Ù. ÀÌ ÀÌ´Ï¼ÅÆ¼ºê´Â ´ãµµÆó¼âÁõ¿¡ ´ëÇÑ ´Ù¾çÇÑ °èÃþÀÇ ÀÎ½Ä Á¦°í, ȯ¾Æ °¡Á·¿¡ ´ëÇÑ Á¶»ç ¹× Áö¿ø, Áø´Ü µµ±¸ ¹× Ä¡·á¹ý ¿¬±¸ ÃËÁø, Àü ¼¼°è ÀÇ·á ±â°ü°úÀÇ Çù·Â ÁõÁø¿¡ ÁßÁ¡À» µÎ¾ú½À´Ï´Ù.

°í·ÉÈ­´Â ³»½Ã°æ ¿ªÇà Ãé´ã°ü Á¶¿µ¼ú ½ÃÀåÀÇ ¼ºÀåÀ» ÃËÁøÇÏ´Â Áß¿äÇÑ ¿äÀÎÀÔ´Ï´Ù. Àü ¼¼°è Àα¸°¡ °í·ÉÈ­µÊ¿¡ µû¶ó ¼öÇ÷ÀÌ ÇÊ¿äÇÑ ¼ö¼ú°ú °°Àº ½Ã¼ú¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ´ã°üÁõ, ºóÇ÷, ¿Ü°úÀû ±¸Ç÷°ú °°Àº ¸¸¼ºÁúȯÀº ¼ºÀÎ Àα¸ÀÇ Áõ°¡¿Í ÇÔ²² °è¼Ó Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÇöÀç ¹Ì±¹¿¡¼­¸¸ 65¼¼ ÀÌ»ó Àα¸°¡ 4,000¸¸ ¸íÀ» ³Ñ¾î¼¹°í, 2050³â±îÁö ±× ¼ö°¡ µÎ ¹è·Î Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¼¼°èº¸°Ç±â±¸(WHO)¿¡ µû¸£¸é 2050³â±îÁö ³ëÀÎ Àα¸ ºñÀ²ÀÌ 22.0%¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Â ÀϺ»Àº ¼¼°è¿¡¼­ °¡Àå °í·É Àα¸°¡ ¸¹Àº ±¹°¡·Î, ÀÌ ½ÃÀå¿¡ ÀáÀçÀûÀÎ ¼ºÀå ±âȸ¸¦ Á¦°øÇϰí ÀÖ½À´Ï´Ù.

¶ÇÇÑ, ÀϺΠÀÇ·á ±â°üÀº Çõ½ÅÀûÀÎ Á¦Ç° ¿¬±¸ ¹× °³¹ßÀ» À§ÇØ ÆÄÆ®³Ê½ÊÀ» Æ÷ÇÔÇÑ ÀÌ´Ï¼ÅÆ¼ºê¸¦ äÅÃÇÏ¿© ½ÃÀå ¼ºÀå¿¡ ¹ÚÂ÷¸¦ °¡Çϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, 2022³â 7¿ù Optica Publishing Group Àú³Î¿¡ °ÔÀçµÈ ¿¬±¸¿¡ µû¸£¸é, School of Biomedical Engineering &Imaging SciencesÀÇ ¿¬±¸ÁøÀº ³»°æ 0.6mmÀÇ ÀÇ·á¿ë ¹Ù´Ã¿¡ »ðÀÔÇÒ ¼ö ÀÖ´Â ±¤À½Çâ À̹Ì¡ ³»½Ã°æ ÇÁ·Îºê¸¦ °³¹ßÇß½À´Ï´Ù. ¶ÇÇÑ ÀΰøÁö´É(AI)À» Ȱ¿ëÇÏ¿© ¿µ»ó Áø´ÜÀ» ºü¸£°Ô ÇÒ ¼ö ÀÖ´Â °¡´É¼ºµµ Á¦½ÃÇß½À´Ï´Ù.

¶ÇÇÑ, M&A ¹× Á¦Ç° ¹ßÇ¥¿Í °°Àº ½ÃÀå ÁøÀÔ ±â¾÷µéÀÌ Ã¤ÅÃÇÏ´Â Àü·«Àû ÀÌ´Ï¼ÅÆ¼ºê´Â ¿¹Ãø ±â°£ µ¿¾È ½ÃÀåÀ» ÁÖµµÇß½À´Ï´Ï´Ù. ¿¹¸¦ µé¾î, 2022³â 4¿ù ¿Ã¸²Çª½º´Â ÁöÇ÷ ºÐ¾ß ±â¼ú °³¹ß¿¡ ÁÖ·ÂÇÏ´Â EndoClot Plus¿Í Á¦ÈÞÇßÀ¸¸ç, EndoClot PlusÀÇ ÁÖ¿ä Á¦Ç° Áß ÇϳªÀÎ EndoClot PHS´Â ¼ÒÈ­°ü ÃâÇ÷À» ºñ¿­Àû, ºñ¿Ü»óÀûÀ¸·Î ÁöÇ÷ÇÒ ¼ö ÀÖ´Â ¹æ¹ýÀÔ´Ï´Ù. À̹ø Çù¾àÀº EndoClot PHS¸¦ ¼ÒÈ­±â³»°ú ÀÇ»çµéÀÌ º¸´Ù ½±°Ô »ç¿ëÇÒ ¼ö ÀÖµµ·Ï ÇÏ¿© ÀÇ·á ½Ã¼ú Áß ÃâÇ÷À» ½Å¼ÓÇϰí È®½ÇÇÏ°Ô ÁöÇ÷ÇÒ ¼ö ÀÖµµ·Ï ÇÏ´Â °ÍÀ» ¸ñÇ¥·Î Çϰí ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú ¹üÀ§

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ³»½Ã°æ ¿ªÇà Ãé´ã°ü Á¶¿µ¼ú ½ÃÀå º¯¼ö, µ¿Çâ, ¹üÀ§

Á¦4Àå ³»½Ã°æ ¿ªÇà Ãé´ã°ü Á¶¿µ¼ú ½ÃÀå : Á¦Ç°º°, ÃßÁ¤¡¤µ¿Ç⠺м®

Á¦5Àå ³»½Ã°æ ¿ªÇà Ãé´ã°ü Á¶¿µ¼ú ½ÃÀå : ½Ã¼ú À¯Çüº°, ÃßÁ¤¡¤µ¿Ç⠺м®

Á¦6Àå ³»½Ã°æ ¿ªÇà Ãé´ã°ü Á¶¿µ¼ú ½ÃÀå : ÃÖÁ¾ ¿ëµµº°, ÃßÁ¤¡¤µ¿Ç⠺м®

Á¦7Àå ³»½Ã°æ ¿ªÇà Ãé´ã°ü Á¶¿µ¼ú ½ÃÀå : Áö¿ªº°, ÃßÁ¤¡¤µ¿Ç⠺м®

Á¦8Àå °æÀï ±¸µµ

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Market Size & Trends:

The global endoscopic retrograde cholangiopancreatography market size was estimated at USD 2.17 billion in 2024 and is anticipated to grow at a CAGR of 8.26% from 2025 to 2030. This growth is majorly driven by the rising incidence of pancreatic and biliary diseases such as gallstones, pancreatitis, and bile duct obstructions are fueling the demand for ERCP procedures. As the population ages and lifestyles change, the prevalence of these conditions is expected to increase, driving market growth. According to Clinical Gastroenterology and Hepatology study published in February 2024, there is an estimated 6% prevalence of gallstones globally, with higher rates observed in females and in South America. According to studies, the incidence rate of gallstones is anticipated to rise sharply over the forecast period, thereby driving the demand for endoscopic retrograde cholangiopancreatography (ERCP) procedures.

Furthermore, advances in endoscopic technology have improved the safety and efficacy of ERCP procedures. For instance, in January 2023, Advantech introduced the MIO-5377R single board computer as a groundbreaking innovation in the field of endoscope technology. This compact and powerful device is designed to address the traditional challenges faced by endoscopes, offering enhanced performance, reliability, and functionality. Moreover, innovations such as high-definition imaging, better maneuverability of endoscopes, and the development of therapeutic accessories have made ERCP a more precise and effective diagnostic and treatment tool. These technological advancements are attracting both healthcare providers and patients to opt for ERCP procedures.

The rise in the adoption of minimally invasive surgical techniques has led to an increased demand for ERCP procedures, which is expected to drive growth in the industry in the upcoming years. For instance, according to the American Cancer Society's annual report published in January 2024, an estimated 41,630 new cases of liver cancer are expected to be diagnosed in the U.S. Additionally, as per the same source, liver cancer is more prevalent in countries in sub- Southeast Asia and Saharan Africa compared to the U.S. It is the most common type of cancer in many of these nations, with over 800,000 new cases diagnosed globally each year. Additionally, liver cancer ranks as a leading cause of cancer-related deaths worldwide, claiming more than 700,000 lives annually.

The high burden of cholangiocarcinoma and hepatocellular carcinoma is expected to boost the demand for endoscopic retrograde cholangiopancreatography for the early detection of such malignancies.

Moreover, the increased awareness about the benefits of early diagnosis and treatment of pancreatic and biliary diseases has led to a higher demand for minimally invasive procedures such as ERCP. For instance, in October 2023. the Biliary Atresia Awareness Committee launched Biliary Atresia Awareness Campaign under the auspices of Gauteng Provincial Solid Organ Transplant Division and the University of the Witwatersrand at Charlotte Maxeke Academic Hospital. The campaign was aimed to raise awareness and support for children affected by biliary atresia, a rare and life-threatening liver disease that affects infants by obstructing or obliterating bile ducts. The initiative was focused on educating diverse demographics about biliary atresia, offering resources and support to affected families, advancing research for diagnostic tools and treatments, and fostering collaboration with medical entities globally.

The aging population is a significant factor driving the growth of the endoscopic retrograde cholangiopancreatography market. As the global population continues to age, there is a growing demand for these procedures, including surgeries that require blood transfusions. Chronic diseases such as caugulopathy, anemia, and surgical blood seeking continue to increase along with the increase in adult population. Currently , there are over 40 million people in the U.S. alone above 65 years and the number are expected to double by 2050. Japan provides potential growth opportunities to this market due to the presence of the highest geriatric population in the globe. According to WHO, the percentage of the geriatric population is expected to reach 22.0% by 2050.

Additionally, several healthcare organizations are adopting initiatives including partnerships for the R&D of innovative products, thereby fueling the market growth. For instance , according to research study published in Optica Publishing Group journal in July 2022, researchers at the School of Biomedical Engineering & Imaging Sciences developed a photoacoustic imaging endoscope probe which can be inserted into a medical needle with an inner diameter as small as 0.6 millimeters. They also suggested that artificial intelligence (AI) could be utilized to accelerate imaging procedures.

Furthermore, the strategic initiatives adopted by the market players, such as mergers, and acquisitions, and product launches are projected to drive the market over the forecast period. For instance, in April 2022, Olympus partnered with EndoClot Plus, a company that focuses on developing technologies in the hemostasis space. One of the key products in EndoClot Plus' portfolio is the EndoClot PHS, a nonthermal, nontraumatic method for achieving hemostasis with gastrointestinal (GI) bleeds. This agreement aims to make the EndoClot PHS more accessible to gastroenterologists, enabling them to stop bleeding rapidly and reliably during medical procedures.

Global Endoscopic Retrograde Cholangiopancreatography Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global endoscopic retrograde cholangiopancreatography market report based on product, procedure, end use and region:

Table of Contents

Chapter 1. Methodology and Scope

Chapter 2. Executive Summary

Chapter 3. Endoscopic Retrograde Cholangiopancreatography Market Variables, Trends & Scope

Chapter 4. Endoscopic Retrograde Cholangiopancreatography Market: Product Estimates & Trend Analysis

Chapter 5. Endoscopic Retrograde Cholangiopancreatography Market: Procedure Estimates & Trend Analysis

Chapter 6. Endoscopic Retrograde Cholangiopancreatography Market: End use Estimates & Trend Analysis

Chapter 7. Endoscopic Retrograde Cholangiopancreatography Market: Regional Estimates & Trend Analysis

Chapter 8. Competitive Landscape

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â